# Validation of recommended definition in identifying elevated blood pressure in adolescents 

Hui Fan PhD ${ }^{1}$ (D) | Yudan Liu MS ${ }^{1}$ | Xingyu Zhang PhD ${ }^{2}$

${ }^{1}$ Department of Preventive Medicine, North Sichuan Medical College, Nanchong, China
${ }^{2}$ Applied biostatistics laboratory, University of Michigan School of Nursing, Ann Arbor, MI, USA

## Correspondence

Hui Fan PhD, Department of Preventive Medicine, North Sichuan Medical College, No. 234 Fujiang Road, Shunqing District, Nanchong 637000, China.
Email: 1577371399@qq.com

## Funding information

This study was supported by the Key Subject Development Program of North Sichuan Medical College (NSMC-M-18-19).


#### Abstract

Recently, the American Academy of Pediatrics (AAP) recommended $120 / 80 \mathrm{~mm} \mathrm{Hg}$ as thresholds for identifying elevated blood pressure (BP) in adolescents aged 13-17 years. The authors aimed to compare the performance of the new definition in identifying elevated BP with traditional percentile-based definition. Data were obtained from the National Health and Nutrition Examination Survey 1999-2014, which included 7485 adolescents aged 13-17 years. Elevated BP was defined using the recommended ( $\geq 120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) and traditional definition ( $\geq 90$ th percentile for sex, age, and height or $120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) presented in AAP guideline. The prevalence of elevated BP was $15.7 \%$ and $17.2 \%$ using the recommended and traditional definition, respectively ( $P$ < .001). The recommended definition had high sensitivity ( $90.9 \%$ ), perfect specificity (100.0\%), perfect positive predictive value ( $100.0 \%$ ), and very high negative predictive value ( $98.1 \%$ ) compared with the traditional definition. The Kappa correlation coefficient between two definitions was 0.94 ( $P<.001$ ). Similar results can be observed in subgroups across sex, age, and sex- and age-specific height percentile except for both sexes with young age and low height percentile. Generally, our results supported the use of the recommended definition for identifying elevated BP in adolescents.


## 1 | INTRODUCTION

Adult hypertension is an important public health challenge worldwide due to its high prevalence and its risk for cardiovascular disease (CVD). ${ }^{1,2}$ Blood pressure (BP) levels in children and adolescents have been increasing alarmingly during the past decades. ${ }^{3,4}$ Elevated BP in children and adolescents may result in target organ damage and increase the risks of adult hypertension and consequent subclinical CVD. ${ }^{5-8}$ Consequently, the early detection of elevated BP in children and adolescents is crucial to promote cardiovascular health and reduce the future CVD risk.

The US Fourth Report recommended the sex-, age-, and heightspecific 90th BP percentiles to define pediatric elevated BP, which was accepted worldwide. ${ }^{9}$ However, the percentile-based definition included hundreds of abnormal BP cutoff values, which resulted in a complex and cumbersome decision process. Elevated BP in children and adolescents was frequently undiagnosed in the clinical practice. ${ }^{10,11}$ As a solution for this problem, the American Academy of Pediatrics (AAP) recommended $120 / 80 \mathrm{~mm} \mathrm{Hg}$ as thresholds to identify elevated

BP in adolescents aged 13-17 years. ${ }^{12}$ The new definition of elevated BP in adolescents was consistent with adult hypertension definition released recently by American College of Cardiology/American Heart Association. ${ }^{12,13}$ To our best knowledge, data are presently limited to compare the performance of the new definition in identifying elevated BP and concomitant cardiometabolic risks with the revised sex-, age-, and height-specific pediatric BP standard presented in AAP guideline. The aim of this study was to evaluate this using the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2014.

## 2 | METHODS

## 2.1 | Study population

NHANES, which has been described in detail elsewhere, is an ongoing, nationally representative, and time-series cross-sectional survey to evaluate health and nutritional status of the resident, civilian, noninstitutionalized US population. ${ }^{14}$ It has been conducted
by the US National Center for Health Statistics of the Centers for Disease Control and Prevention since 1999 in 2-year cycle. It consists of questionnaire survey, physical examination, and laboratory tests in each cycle. The protocols for NHANES were approved by the National Center for Health Statistics of the Centers for Disease Control and Prevention Institutional Review Board. All the participants and their guardians provided signed informed consent.

We pooled data based on NHANES 1999-2014. The present study was restricted to 9039 individuals aged 13-17 years. Participants with incomplete data on age, sex, race, and height were excluded ( $n=78$ ). Participants who did not have 3 consecutive BP values were also excluded ( $n=1476$ ). After these exclusions were conducted, a total of 7485 participants were included in the current analyses.

## 2.2 | General examinations

In the mobile examination center, BP measurements were conducted in the sitting position after 5-minute resting. BP was measured by auscultation by trained officers. The Korotkoff first and fifth phases were used to define systolic BP (SBP) and diastolic BP (DBP), respectively. Three consecutive BP readings were recorded, and the mean of the last two readings was used in the analysis. Height was measured without shoes by trained staff using calibrated equipment. Weight was measured using standard and calibrated equipment. The questionnaire survey was conducted to collect information on demographic data including sex, age, and race.

## 2.3 | Definition of elevated BP in adolescents

Childhood BP values were classified as normal BP, elevated BP, and hypertension stage 1 and stage 2 in the AAP guideline. ${ }^{12}$ In the present study, we consider children with elevated BP, and hypertension stage 1 and stage 2 identified by the AAP guideline as having "elevated BP."

### 2.3.1 | Recommended definition

Elevated $B P$ in adolescents was defined as $B P \geq 120 / 80 \mathrm{~mm} \mathrm{Hg} .{ }^{12}$

### 2.3.2 | Traditional definition

Elevated BP in adolescents was defined as BP $\geq 90$ th percentile for sex, age, and height ( $o r \geq 120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) according to new normative pediatric BP tables issued by the AAP guidelines. ${ }^{12}$ The new normative pediatric BP tables were developed based on normal-weight children, and the details of the development process have been described elsewhere. ${ }^{15}$

## 2.4 | Cardiometabolic risks

The cardiometabolic risk assessment included body mass index (BMI), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride
(TG), and glycated hemoglobin. BMI was calculated as weight divided by height squared $\left(\mathrm{kg} / \mathrm{m}^{2}\right)$. Laboratory data consisted of TC, HDL-C, LDL-C, TG, and glycated hemoglobin were available for adolescents aged 13-17 years. NHANES Laboratory Procedures Manual released information about sample collection, preservation, measurement procedures, and method. ${ }^{16}$

## 2.5 | Statistical analysis

Through the use of traditional definition, BPs were classified as normal and elevated BP. Then, BP categories were conducted as defined in the recommended definition. We will report data as means (SEs) and frequencies as appropriate stratified by BP category, which were weighted to represent the US population.

Compared with the traditional definition, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated to assess the performance of the recommended definition for identifying pediatric elevated BP. The Kappa correlation coefficient was calculated to evaluate the agreement between two aforementioned definitions. Height percentiles were calculated according to the US Centers for Disease Control and Prevention data. ${ }^{17}$ Subgroup analyses were conducted by demographic characteristics (sex and age), and sex- and age-specific height percentile.

Participants were categorized into four groups based on the combinations of the recommended and traditional definitions: participants with normal BP identified by both definitions, participants with elevated BP detected by the traditional definition but normal BP reclassified by the recommended definition, participants with normal BP detected by the traditional definition but elevated BP reclassified by the recommended definition, and participants with elevated BP diagnosed by both definitions. The differences were tested for age, sex, height, and race using the univariate linear regression models or chi-square test between groups. Meanwhile, multiple linear regressions after adjusted for sex, age, and height were used to test the differences of cardiometabolic risks between groups (coded as the dummy variables). The analyses were adjusted for sampling weights, primary sampling units, and strata to account for the complex survey design of NHANES 1999-2014. ${ }^{18}$ All data analyses were conducted with the SAS version 9.2 (SAS Institute). Statistical significance was inferred at a 2 -tailed $P<.05$.

## 3 | RESULTS

A total of 7485 participants were included in the present study. The prevalence of elevated BP was $15.7 \%$ and $17.2 \%$ using the recommended and traditional definitions, respectively ( $P$ < .001). Characteristics of the participants stratified by BP category as defined in the recommended and traditional classifications are presented in Tables S1 and S2. Table 1 summarizes the demographic and cardiometabolic characteristics of all participants considering the weight for survey.

TABLE 1 Characteristics of the study participants by BP category weighted for survey

|  |  | Normal BP |  | Elevated BP |
| :--- | :--- | :--- | :--- | :--- | :--- |

Note: Data are presented as means (SEs) or frequencies (\%) as appropriate.
Some data were missing for cardiometabolic variables, and available data are shown in Table S2.
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.

Table 2 shows the performance of the recommended definition for identifying elevated BP. Compared with the traditional definition, the recommended definitions had high sensitivity (90.9\%), perfect specificity (100.0\%), perfect PPV (100.0\%), and very high NPV (98.1\%). The Kappa correlation coefficient between two definitions was 0.94 ( $P<.001$ ). Similar results can be obtained in subgroup across sex and age. Both specificity and PPV were perfect (both $100 \%$ ) in all subgroups across sex, age, and sex- and age-specific height percentile. Sensitivity differed substantially comparing data at low vs high height percentile among both sexes with young age.

Table 3 presents the comparison of demographic and cardiometabolic characteristics between groups classified by the combinations of two definitions. There are $1172,117,6196$, and 0 participants with elevated BP diagnosed by both definitions, elevated BP detected by the traditional definition but normal BP reclassified by the recommended definition, normal BP identified by both definitions, and normal BP detected by the traditional definition but elevated BP reclassified by the recommended definition, respectively. A total of 117 reclassified participants were younger and shorter and had lower proportion of male than 6196 participants who remained in the normal BP category (all $P_{s}<0.05$ ). Between these two groups, the cardiometabolic risk (ever

BMI, TC, HDL-C, LDL-C, TG, and glycated hemoglobin) was not significantly different with adjustment for sex, age, and height (all $P_{s}>0.05$ ).

## 4 | DISCUSSION

The present study showed that recommended definition performed well in identifying elevated BP in adolescents aged 13-17 years, with high sensitivity, perfect specificity, perfect PPV, and high NPV. Sensitivity differed greatly comparing data at low vs high height percentile among both sexes with young age. This study also demonstrated that the differences of cardiometabolic risks were not significant between the participants with elevated BP detected by the traditional definition but normal BP reclassified using the recommended definition and those with normal BP identified using both definitions.

To improve the detection of pediatric elevated BP, several simplified definitions were developed. ${ }^{19-22}$ Cross-sectional studies suggested that those simplified definitions had high sensitivities and moderate specificities in comparison with the Fourth Report. ${ }^{19-21}$ These results were also confirmed by a recent metaanalysis showing many simplified definitions as the accurate

TABLE 2 Performance of the recommended definition for identifying elevated BP

|  | Sensitivity <br> (\%) | Specificity <br> (\%) | PPV <br> (\%) | NPV <br> (\%) | Kappa co- $_{\text {efficient }^{*}}$ |
| :---: | :--- | :--- | :--- | :--- | :--- |
| All partici- <br> pants | 90.9 | 100 | 100 | 98.1 | 0.94 |
| Sex |  | 100 | 100 | 98.7 | 0.97 |
| Male | 95.5 | 100 | 100 | 97.7 | 0.88 |
| Female | 81.1 |  |  |  |  |
| Age |  | 100 | 100 | 97.1 | 0.87 |
| 13 y | 79.9 | 100 | 100 | 97.7 | 0.91 |
| 14 y | 85.5 | 100 | 100 | 99.0 | 0.97 |
| 15 y | 94.8 | 100 | 100 | 98.5 | 0.96 |
| 16 y | 94.2 | 100 | 100 | 98.6 | 0.97 |
| 17 y | 94.8 |  |  |  |  |

Height percentiles among male aged $13 y$

| $<25$ | 40.0 | 100 | 100 | 92.4 | 0.54 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 71.4 | 100 | 100 | 94.5 | 0.81 |
| $50 \sim$ | 80.0 | 100 | 100 | 97.2 | 0.88 |
| $\geq 75$ | 100 | 100 | 100 | 100 | 1 |

Height percentiles among male aged 14 y

| $<25$ | 64.7 | 100 | 100 | 94.3 | 0.76 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 96.8 | 100 | 100 | 99.3 | 0.98 |
| $50 \sim$ | 86.8 | 100 | 100 | 96.8 | 0.91 |
| $\geq 75$ | 97.8 | 100 | 100 | 99.5 | 0.99 |

Height percentiles among male aged 15 y

| $<25$ | 95.8 | 100 | 100 | 99.1 | 0.97 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $50 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $\geq 75$ | 100 | 100 | 100 | 100 | 1 |

Height percentiles among male aged 16 y

| 25 | 93.6 | 100 | 100 | 98.1 | 0.96 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $50 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $\geq 75$ | 100 | 100 | 100 | 100 | 1 |

Height percentiles among male aged 17 y

| $<25$ | 95.3 | 100 | 100 | 98.4 | 0.97 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $50 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $\geq 75$ | 100 | 100 | 100 | 100 | 1 |


| Height percentiles among female aged $13 y$ |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $<25$ | 70.0 | 100 | 100 | 96.4 | 0.81 |
| $25 \sim$ | 72.7 | 100 | 100 | 97.3 | 0.83 |
| $50 \sim$ | 63.6 | 100 | 100 | 97.9 | 0.77 |
| $\geq 75$ | 84.6 | 100 | 100 | 97.3 | 0.90 |


| Height percentiles among female aged $14 y$ |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 25 | 50.0 | 100 | 100 | 96.4 | 0.65 |
| $25 \sim$ | 81.8 | 100 | 100 | 97.9 | 0.89 |

(Continues)

TABLE 2 (Continued)

|  | Sensitivity <br> $(\%)$ | Specificity <br> $(\%)$ | PPV <br> $(\%)$ | NPV <br> $(\%)$ | Kappa co- <br> efficient* |
| :---: | :--- | :--- | :--- | :--- | :--- |
| 50~ | 91.7 | 100 | 100 | 98.9 | 0.95 |
| $\geq 75$ | 81.0 | 100 | 100 | 97.2 | 0.88 |
| Height percentiles among female aged 15 y |  |  |  |  |  |
| $<25$ | 82.6 | 100 | 100 | 97.8 | 0.89 |
| $25 \sim$ | 70.0 | 100 | 100 | 96.6 | 0.81 |
| $50 \sim$ | 100 | 100 | 100 | 100 | 1 |
| $\geq 75$ | 94.4 | 100 | 100 | 99.2 | 0.97 |

Height percentiles among female aged 16 y

| $<25$ | 83.3 | 100 | 100 | 97.9 | 0.90 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $25 \sim$ | 77.4 | 100 | 100 | 96.0 | 0.85 |
| $50 \sim$ | 80.0 | 100 | 100 | 97.8 | 0.88 |
| $\geq 75$ | 94.1 | 100 | 100 | 99.3 | 0.97 |


| Height percentiles among female aged 17 y |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $<25$ | 82.6 | 100 | 100 | 98.2 | 0.90 |
| $25 \sim$ | 84.2 | 100 | 100 | 98.1 | 0.91 |
| $50 \sim$ | 75.0 | 100 | 100 | 96.3 | 0.84 |
| $\geq 75$ | 93.8 | 100 | 100 | 99.2 | 0.96 |

Abbreviations: BP, blood pressure; NPV, negative predictive value; PPV, positive predictive value.
*All Ps < . 001.
screening tools. ${ }^{22}$ Of note, several previous studies emphasized the importance of BP reassessment using the Fourth Report after identifying children with elevated BP by the simplified definition. ${ }^{19-22}$

In 2017, AAP updated the Fourth Report. ${ }^{12}$ To use friendly and align with adult hypertension guidelines, the most prominent change in the AAP updated guideline was the recommendation of absolute BP thresholds (120/80 mm Hg) on the diagnosis of elevated BP in adolescents aged 13-17 years. In other words, the simplified definition $(\geq 120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) replaced traditional percentile-based definition for identifying elevated BP in adolescents. ${ }^{12}$ There were limited data regarding the difference between the recommended and traditional percentile-based definition revealed by AAP guidelines for adolescents. Our findings showed that the recommended definition had high sensitivity, perfect specificity (100\%), perfect PPV (100\%), and very high NPV compared with the traditional definition. Additionally, the agreement between two definitions was high.

Good performance of the recommended definition can be expected. Considering the characteristics of the recommended $(\geq 120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) and traditional definition ( $\geq$ sex-, age-, and height-specific 90th BP percentiles or $120 / 80 \mathrm{~mm} \mathrm{Hg}$, whichever is lower), the reclassification of BP category can only be observed among participants whose BP was greater than corresponding sex-, age-, and height-specific 90th BP percentiles and <120/80 mm Hg. Consequently, only 117 (1.6\%) of all participants, who were detected as elevated BP by the traditional definition, were reclassified as normal BP by the recommended definition. Meanwhile, there were 0

TABLE 3 Comparison of the characteristics between groups classified by the combinations of two definitions

|  | Group 1 | Group 2 | Group 3 | P |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Group 1 vs <br> Group 3 | Group 2 vs <br> Group 3 |
| Demographic characteristics ${ }^{\text {a }}$ |  |  |  |  |  |
| No. | 1172 | 117 | 6196 |  |  |
| Age (y) | 15.9 (0.1) | 15.0 (0.2) | 15.4 (0.02) | <. 001 | . 009 |
| Male (\%) | 70.4 | 30.8 | 46.0 | <.001 ${ }^{\text {b }}$ | . $012{ }^{\text {b }}$ |
| Height (cm) | 170.5 (0.4) | 159.3 (0.7) | 165.9 (0.2) | <. 001 | <. 001 |
| Race |  |  |  | . $503{ }^{\text {b }}$ | . $994{ }^{\text {b }}$ |
| White (\%) | 57.5 | 60.0 | 60.2 |  |  |
| Black (\%) | 18.9 | 13.9 | 13.5 |  |  |
| Mexican <br> American <br> (\%) | 13.0 | 11.2 | 12.1 |  |  |
| Hispanic (\%) | 5.3 | 6.4 | 6.7 |  |  |
| Others (\%) | 5.3 | 8.5 | 7.5 |  |  |
| Cardiometabolic characteristics ${ }^{\text {c }}$ |  |  |  |  |  |
| BMI (kg/m ${ }^{2}$ ) | 26 (0.2) | 23.2 (0.7) | 22.9 (0.1) | <. 001 | . 293 |
| Total cholesterol (mg/dL) | 162 (1.3) | 160.6 (3.3) | 156.1 (0.5) | <. 001 | . 686 |
| HDL cholesterol (mg/dL) | 48.3 (0.5) | 53.5 (2.3) | 50.9 (0.2) | . 036 | . 567 |
| LDL cholesterol (mg/dL) | 95.7 (2.4) | 88.3 (3.9) | 87.2 (0.6) | <. 001 | . 649 |
| Triglyceride (mg/dL) | 95.9 (3.9) | 85.3 (11.7) | 80.8 (1.3) | . 001 | . 648 |
| Glycated hemoglobin (\%) | 5.2 (0.02) | 5.5 (0.2) | 5.2 (0.01) | . 570 | . 145 |

Notes: Data are presented as means (SEs) or frequencies (\%) as appropriate. Some data were missing for cardiometabolic variables.
Group 1: participants with elevated BP diagnosed by both definitions; Group 2: participants with elevated BP detected by the traditional definition but normal BP reclassified by the recommended definition; Group 3: participants with normal BP identified by both definitions. There are 0 participants with normal BP detected by the traditional definition but elevated BP reclassified by the recommended definition.
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
${ }^{\text {a }}$ Comparison of demographic characteristics between groups was performed using univariate linear regression models or chi-square test.
${ }^{\text {b }}$ Compared with adjusted alpha levels (0.05/2) due to multiple comparisons.
${ }^{\text {c Comparison of cardiometabolic characteristics between groups (coded as the dummy variables) }}$ was performed using multiple linear regressions after adjusted for sex, age, and height.
participants with normal BP detected by the traditional definition but elevated BP reclassified by the recommended definition.

Previous simplified tools did not have perfect specificity/PPV and very high sensitivity/NPV. ${ }^{19-22}$ Because of many diagnostic thresholds, these tools had the relatively low simplified degree. ${ }^{19-22}$ On the contrary, 120/80 threshold was simple and user-friendly. Clinicians can use the recommended definition to quickly identify elevated BP. Of note, sensitivity differed greatly comparing data at low vs high height percentile among both sexes with young age. The recommended definition was used with caution among younger (eg,

13 years) and shorter (eg, <sex- and age-specific 25th height percentiles) participants, whose 90th BP percentiles for sex, age, and height, as described in the AAP guidelines, ${ }^{12}$ were obviously lower than 120/80 mm Hg.

Whether the participants with elevated BP as defined in the traditional definition but normal BP as reclassified in the recommended definition had the increased risks of CVD compared to those with normal BP diagnosed by both definitions has not been clarified. In the current study, our findings indicated that the differences of cardiometabolic risks were not significant between these two groups,
suggesting that participants from these two groups may exhibit the similar risks of future CVD. Our results were partly supported by a cohort study with 27.1-year follow-up, which demonstrated that the recommended definition ( $120 / 80 \mathrm{~mm} \mathrm{Hg}$ ) performed equally with the Fourth Report in predicting adult hypertension and subclinical CVD. ${ }^{8}$ Similarly, previous publications summarized the convincing evidence and underscored the importance of conserving optimal BP $(<120 / 80 \mathrm{~mm} \mathrm{Hg})$ in primordial prevention of CVD for adolescents. ${ }^{23}$

The strengths of this study included the nationally representative data from NHANES, the large sample size, and the high quality of data measurement (trained examiners and calibrated instruments), which made our results convincing and generalizable to US adolescents aged 13-17 years. Several limitations should be noted in the current study. First, NHANES was conducted in the US population, which limits the generality of our results to other population. Second, due to unavailable long-term follow-up data, we cannot assess whether adolescents whose BP was reclassified as normal BP had increased risk of CVD compared with those with normal BP detected by both definitions. Further cohort studies are necessary to bridge this gap. Finally, the small number of participants who underwent BP reclassification and laboratory assessment did not allow us to perform further analysis by abnormal cutoffs of cardiometabolic risks. Further studies should fill in this gap.

In summary, our study suggested that the recommended definition performed well in identifying elevated BP in adolescents compared with the traditional standard. Our results supported the use of the recommended definition for identifying elevated BP in adolescents aged 13-17 years.

## ACKNOWLEDGMENT

We thank the National Center for Health Statistic of Centers for Disease Control and Prevention for sharing NHANES data.

## CONFLICT OF INTEREST

The authors have no conflicts of interest relevant to this article to disclose.

## AUTHOR CONTRIBUTIONS

Dr Fan conceptualized and designed the study, carried out the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript; Ms Liu designed the data collection instruments, coordinated data collection, and critically reviewed and revised the manuscript; Dr Zhang critically reviewed and revised the manuscript; and all authors approved the final manuscript as submitted.

## ORCID

Hui Fan (ID https://orcid.org/0000-0003-3920-0600

## REFERENCES

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
2. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2:634-647.
3. Dong B, Wang HJ, Wang Z, Liu JS, Ma J. Trends in blood pressure and body mass index among Chinese children and adolescents from 2005 to 2010. Am J Hypertens. 2013;26:997-1004.
4. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S213-S256.
5. Hanevold C, Waller J, Daniels S, Portman R, Sorof J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113:328-333.
6. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117:3171-3180.
7. Fan H, Hou D, Liu J, Yan Y, Mi J. Performance of 4 definitions of childhood elevated blood pressure in predicting subclinical cardiovascular outcomes in adulthood. J Clin Hypertens (Greenwich). 2018;20:508-514.
8. Xi B, Zhang T, Li S, et al. Can pediatric hypertension criteria be simplified? A prediction analysis of subclinical cardiovascular outcomes from the Bogalusa Heart Study. Hypertension. 2017;69:691-696.
9. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
10. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874-879.
11. Kaelber DC, Liu W, Ross M, et al. Diagnosis and medication treatment of pediatric hypertension: a retrospective cohort study. Pediatrics. 2016;138:e20162195.
12. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.
13. Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:1269-1324.
14. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: questionnaires, datasets, and related documentation. https://wwwn.cdc.gov/nchs/nhanes/Defau It.aspx. Accessed September 6, 2018.
15. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008;167:653-666.
16. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) laboratory procedures manual 2011. http://www.cdc.gov/nchs/data/nhanes/ nhanes_11_12/2011-12_Laboratory_Procedures_Manual.pdf. Accessed September 6, 2018.
17. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat. 2002;246:1-190.
18. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: analytic guidelines, 2011-2012. 2013. http://www.cdc.gov/nchs/data/nhanes/analytic_guidelines_11_ 12.pdf. Accessed September 6, 2018.
19. Ma C, Kelishadi R, Hong YM, et al. Performance of eleven simplified methods for the identification of elevated blood pressure in children and adolescents. Hypertension. 2016;68:614-620.
20. Ma C, Liu Y, Liu X, Yin F, Lu Q. Comparison of different screening methods for hypertension in han adolescents. Clin Pediatr. 2016;55:363-367.
21. Mourato FA, Lima Filho JL, Mattos SS. Comparison of different screening methods for blood pressure disorders in children and adolescents. J Pediatr. 2015;91:278-283.
22. Ma C, Wang R, Liu Y, et al. Performance of user-friendly screening tools for elevated blood pressure in children. Pediatrics. 2017;139:e20161986.
23. Falkner B, Gidding SS. Is the SPRINT blood pressure treatment target of $120 / 80 \mathrm{~mm} \mathrm{Hg}$ relevant for children? Hypertension. 2016;67:826-828.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Fan H, Liu Y, Zhang X. Validation of recommended definition in identifying elevated blood pressure in adolescents. J Clin Hypertens. 2019;21:
1343-1349. https://doi.org/10.1111/jch. 13640

